Showing 2141-2150 of 2319 results for "".
- Alma Lasers Releases Soprano ICE Multi-Platform Hair Removal System with Alex™ Technologyhttps://practicaldermatology.com/news/alma-lasers-releases-soprano-ice-multi-platform-hair-removal-system-with-alex-technology/2458984/Alma Lasers added the Soprano ICE ™ platform to its product portfolio. The Soprano ICE Multi-Platform combines the high absorption benefits of the Alexandrite (755nm) wavelength with the advantages of a diode laser providing more comfort for the patient during hair removal and lower mainten
- L'Oreal International Extends Deadline for Social Responsibility in Dermatology Awardshttps://practicaldermatology.com/news/loreal-international-extends-deadline-for-social-responsibility-in-dermatology-awards/2458996/L’Oréal announced today the extension of the closing date of its International Awards for Social Responsibility in Dermatology to April 15th 2015. Patients with dermatological conditions may frequently face discrimination and feel socially excluded,
- POWER Study Suggests EpiDuo plus Doxycycline May be an Alternative to Isotretinoinhttps://practicaldermatology.com/news/power-study-suggests-epiduo-plus-doxycycline-may-be-an-alternative-to-isotretinoin/2459000/Doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO) is an alternative to isotretinoin in patients intolerant to, or unable or unwilling to take, oral isotretinoin, and is an option for treatment of severe nodular acne, according to a new study. Findings suggest that th
- Pfizer Announces FDA Acceptance For Review of Supplemental New Drug Application for Oral Xeljanz For Plaque Psoriasishttps://practicaldermatology.com/news/pfizer-announces-fda-acceptance-for-review-of-supplemental-new-drug-application-for-oral-xeljanz-for-plaque-psoriasis/2459011/The FDA accepted for review Pfizer Inc.’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) 5mg and 10mg tablets, a Janus kinase (JAK) inhibitor, the first in a new class of oral medicines being investigated for the treatment of adult patients with moderate to sever
- InMed Initiates Program Targeting Epidermolysis Bullosa Simplexhttps://practicaldermatology.com/news/inmed-initiates-program-targeting-epidermolysis-bullosa-simplex/2459014/InMed Pharmaceuticals Inc. added a new therapy to its pipeline: INM-750, for the treatment of Epidermolysis bullosa simplex(EBS), a rare genetically inherited skin disorder. INM-750 is designed to suppress pathological skin growth, differentiation, and inflammation that are signature characterist
- FDA Approves First IL-17A antagonist Cosentyx (secukinumab) from Novartis for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-first-il-17a-antagonist-cosentyx-secukinumab-from-novartis-for-moderate-to-severe-plaque-psoriasis/2459019/The FDA approved Cosentyx™ (secukinumab) from Novartis for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Cosentyx is the first approved psoriasis medication to selectively bind to IL-17A and inhibit its intera
- Celsus Therapeutics Receives FDA Allowance of IND in Atopic Dermatitishttps://practicaldermatology.com/news/celsus-therapeutics-receives-fda-allowance-of-ind-in-atopic-dermatitis/2459026/Celsus Therapeutics will expand its clinical program in atopic dermatitis in the US, now that the FDA has allowed its Investigational New Drug Application (IND) for the clinical development of MRX-6 Cream 2% in patients with atopic dermatitis. The Com
- Dermira and UCB Announce Start of Phase 3 Program for Cimzia® (Certolizumab Pegol) in Psoriasishttps://practicaldermatology.com/news/dermira-and-ucb-announce-start-of-phase-3-program-for-cimzia-certolizumab-pegol-in-psoriasis/2459027/Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (NASDAQ: DERM), and UCB, a global biop
- XTRAC Offering Rebate for Excimer Laser Treatmentshttps://practicaldermatology.com/news/xtrac-offers-coupon-for-vitiligo-treatments/2459029/PhotoMedex is offering a limited-time rebate for patients treated with the XTRAC Excimer Laser from January 1 through March 31, 2015. The rebate is worth up to $100 per treatment and can be used to offset the costs of insurance deduc
- FDA Grants Bristol-Myers Squibb's Opdivo Accelerated Approval for Melanomahttps://practicaldermatology.com/news/fda-grants-bristol-myers-squibbs-opdivo-accelerated-approval-for-melanoma/2459039/The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilim